Breaking Oncology / Hematology | Physician's Weekly
Advertisement

Breaking Oncology / Hematology

FDA Approves Amivantamab for NSCLC with EGFR Mutations

The first targeted treatment for this population requires Dx with an FDA-approved test The FDA granted intravenous amivantamab-vmjw (Rybrevant) accelerated approval for adult patients with non-small cell lung cancer with...

FDA OKs Pegcetacoplan for Paroxysmal Nocturnal Hemoglobinuria

Patients with rare blood disease can access drug through REMS The FDA approved subcutaneous pegcetacoplan (Empaveli) for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare and serious blood disease that affects 1-1.5...

Loading

Advertisement

For latest news and updates
Email-id is invalid